Kirstie N Anderson1, John M Shneerson. 1. Regional Centre for Neurosciences, Newcastle General Hospital, Newcastle upon Tyne, UK. kirstieanderson@nhs.net
Abstract
STUDY OBJECTIVES: REM sleep behavior disorder (RBD) is characterized by loss of the normal muscle atonia during REM sleep associated with disruptive motor activity related to the acting out of dreams. There is frequently injury to the patient or bed partner, and treatment is usually required. Clonazepam has been the first-line therapy for many years, with 2 large case series reporting efficacy with few side effects in the majority of patients. However, long-acting hypnotics in the elderly or those with cognitive impairment can be associated with adverse events especially unacceptable daytime sedation, confusion, and exacerbation of existing sleep apnea. METHODS: We reviewed 39 patients with confirmed RBD who were treated within our regional sleep center, assessing both efficacy and side effects of drug therapies. RESULTS: Adverse effects were reported by 58% of the patients using clonazepam, with 50% either discontinuing the drug or reducing the dose. This prompted us review the side effects of clonazepam in detail and to look for alternative therapies. We report several novel and effective therapies, in particular zopiclone, in a series of patients under long-term follow-up for RBD. CONCLUSIONS: There are alternatives to clonazepam therapy for RBD which can be as effective and may be better tolerated.
STUDY OBJECTIVES:REM sleep behavior disorder (RBD) is characterized by loss of the normal muscle atonia during REM sleep associated with disruptive motor activity related to the acting out of dreams. There is frequently injury to the patient or bed partner, and treatment is usually required. Clonazepam has been the first-line therapy for many years, with 2 large case series reporting efficacy with few side effects in the majority of patients. However, long-acting hypnotics in the elderly or those with cognitive impairment can be associated with adverse events especially unacceptable daytime sedation, confusion, and exacerbation of existing sleep apnea. METHODS: We reviewed 39 patients with confirmed RBD who were treated within our regional sleep center, assessing both efficacy and side effects of drug therapies. RESULTS: Adverse effects were reported by 58% of the patients using clonazepam, with 50% either discontinuing the drug or reducing the dose. This prompted us review the side effects of clonazepam in detail and to look for alternative therapies. We report several novel and effective therapies, in particular zopiclone, in a series of patients under long-term follow-up for RBD. CONCLUSIONS: There are alternatives to clonazepam therapy for RBD which can be as effective and may be better tolerated.
Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188
Authors: N Takeuchi; N Uchimura; Y Hashizume; M Mukai; Y Etoh; K Yamamoto; T Kotorii; H Ohshima; M Ohshima; H Maeda Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188
Authors: Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali Journal: Neurotox Res Date: 2012-06-28 Impact factor: 3.911
Authors: R Nisha Aurora; Rochelle S Zak; Rama K Maganti; Sanford H Auerbach; Kenneth R Casey; Susmita Chowdhuri; Anoop Karippot; Kannan Ramar; David A Kristo; Timothy I Morgenthaler Journal: J Clin Sleep Med Date: 2010-02-15 Impact factor: 4.062